ArticleJournal of virology2021
CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques.
Open access · hybridAbstract read
In one paragraph
Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting NF-κB signaling for HIV latency reversal: Mechanisms, challenges, and therapeutic perspectives.Virus research · 2026Review
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- Review
- Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation.Journal of virology · 2026Article
- Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques.The Journal of clinical investigation · 2026Article
- Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency.Nature communications · 2025Article
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Advancing Toward a Human Immunodeficiency Virus Cure: Initial Progress on a Difficult Path.Infectious disease clinics of North America · 2024Review
- Review
- Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cellsMicrobiology spectrum · 2024Article
- Recent advances in CD8Heliyon · 2023Review
- CD8Immunity · 2023Article
- Combination Antiretroviral Therapy and Immunophenotype of Feline Immunodeficiency Virus.Viruses · 2023Article
- CD8Nature microbiology · 2023Article
- Review
- Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques.Nature communications · 2022Article
- HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies.Current HIV/AIDS reports · 2022Review
- β-catenin regulates HIV latency and modulates HIV reactivation.PLoS pathogens · 2022Article
- So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.Viruses · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Maud MavignerDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0001-9898-317X
Laura E LiaoTheoretical Biology and Biophysics Group, MS-K710, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Alyssa D BrooksDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Ruian KeTheoretical Biology and Biophysics Group, MS-K710, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Cameron MattinglyDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Nils SchoofDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Julia McBrienYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Diane CarnathanYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Shan LiangYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Thomas H VanderfordYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Mirko PaiardiniYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Deanna KulpaYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-0411-7295
Jeffrey D LifsonAIDS and Cancer Virus Program Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Richard M DunhamViiV Healthcare, Research Triangle Park, North Carolina, United States of America.ORCID https://orcid.org/0000-0003-4542-2330
Kirk A EasleyDepartment of Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
David M MargolisUniversity of North Carolina HIV Cure Center and Department of Medicine, UNC Chapel Hill, Chapel Hill, North Carolina, United States of America.
Alan S PerelsonTheoretical Biology and Biophysics Group, MS-K710, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.ORCID https://orcid.org/0000-0002-2455-0002
Guido SilvestriYerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America ann.m.chahroudi@emory.edu.ORCID https://orcid.org/0000-0001-7479-9546
Emory University · USLos Alamos National Laboratory · USUniversity of North Carolina at Chapel Hill · USFrederick National Laboratory for Cancer Research · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MB and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative SupplementUM1AI124436 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO, HUNTER, ERIC · 2016 to 2021
$42.3MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MAntiviral role of CD8+ T cells in ART-treated SIV-infected macaquesR01AI125064 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2016 to 2025
$8.7MViral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5MModeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0MImmune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7MModeling the HIV latent reservoir, latency reversal and immunotherapeutics for HIV cureR01AI152703 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI KE, RUIAN · 2020 to 2024
$3.0MHigh resolution profiling and computational modeling of influenza virus-immune dynamics during natural infectionU01AI186993 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Christopher Byron Brooke, Ruian Ke · 2025 to 2026
$2.7MNCI NIH HHS 75N91019D00024NIAID NIH HHS P01 AI131365NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI125064NIAID NIH HHS R01 AI152703NIAID NIH HHS U01 AI186993NIAID NIH HHS UM1 AI124436NIAID NIH HHS UM1 AI126619NIH HHS P51 OD011132NIH HHS R01 OD011095NIH HHS U42 OD011023
Abstract
Inducing latency reversal to reveal infected cells to the host immune system represents a potential strategy to cure HIV infection. In separate studies, we have previously shown that CD8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.